Try Claude
Nutrition DataNutrition facts for any food
AI Tools for Biochemists
AI tools that help biochemists search scientific literature, look up chemical compounds, track clinical trials, find research funding, and accelerate drug discovery workflows.
Get started for free
Works in Chat, Cowork and Code
Target Class
Receptor tyrosine kinase · ErbB family
Known Inhibitors
Erlotinib, gefitinib, afatinib, osimertinib (3rd gen)
Key Mutations
Exon 19 del, L858R (sensitizing) · T790M (resistance)
GHS Hazard (gefitinib)
H361 reproductive toxicity · H400 aquatic hazard
Clinical Relevance
Primary oncology target — NSCLC, head & neck
Chemical compound and safety research
Look up any compound by name, CAS number, or formula to get molecular weight, structure data, GHS safety classifications, and known biological activity. Prepare lab safety sheets and confirm reagent properties before experiments.
Look up sodium dodecyl sulfate: molecular formula, MW, GHS hazard classification, and any known protein interactions.
SDS (C₁₂H₂₅NaSO₄, MW 288.38g/mol): GHS hazard — irritant (skin/eyes), H315/H319. Anionic detergent that denatures proteins by binding hydrophobic regions; widely used in PAGE for size-based separation.
ToolRouter lookup_compound
Formula / MW
C₁₂H₂₅NaSO₄ · 288.38 g/mol
GHS Hazards
H315 skin irritant · H319 eye irritant
Biological Activity
Anionic detergent · denatures proteins by hydrophobic binding
Primary Use
SDS-PAGE for size-based protein separation
Scientific literature search and citation mining
Search millions of peer-reviewed papers to find the latest findings on any biochemical target, pathway, or technique. Mine citation networks to identify landmark papers and emerging researchers in your field.
Find the 10 most-cited papers on mTOR pathway inhibition in cancer from 2020 onwards. Show journal, citation count, and key finding.
Retrieved 10 papers. Top: "mTORC1/2 dual inhibition overcomes rapamycin resistance" (Nature Cancer, 2021, 1,204 citations). 6 of 10 focus on combination therapy strategies.
ToolRouter search_papers
TitleJournalYear
mTORC1/2 dual inhibition overcomes rapamycin resistanceNature Cancer2021
Combination mTOR + immunotherapy in RCCJ Clin Oncol2022
Allosteric mTOR inhibitors in TNBCCancer Cell2023
10 papers retrieved · 6 focus on combination therapy strategies
Clinical trial monitoring
Track active, recruiting, and completed clinical trials for compounds and targets you research. Understand the competitive clinical landscape and identify potential collaboration or publication opportunities.
Find Phase 2 and Phase 3 trials currently recruiting for PD-1/PD-L1 inhibitors in triple-negative breast cancer. Include sponsor, enrollment target, and estimated completion.
Found 14 active recruiting trials. 4 are Phase 3. Largest: Merck KEYNOTE-756 (n=1,250, est. completion Q3 2027). 3 trials are testing combination regimens with PARP inhibitors.
ToolRouter search_trials
TrialPhaseEnrollment
KEYNOTE-756 (Merck)Phase 31,250
IMpassion031 ExtensionPhase 3640
NeoTRIPaPDL1Phase 2280
14 active recruiting trials · 4 Phase 3 · 3 PARP combination regimens
Drug information and regulatory lookups
Access FDA-approved drug labeling data including mechanisms of action, indications, dosing, warnings, and contraindications. Useful for target validation, repurposing research, and competitor analysis.
Pull the FDA label for osimertinib: mechanism of action, approved indications, and major drug interactions.
Osimertinib (Tagrisso): EGFR TKI, 3rd generation. Approved for NSCLC with exon 19 deletions or L858R/T790M mutations. Major interactions: strong CYP3A4 inducers reduce efficacy by ~78%. Black box: QTc prolongation.
ToolRouter search_drug
Class
3rd-generation EGFR TKI · irreversible
Indications
NSCLC with exon 19 del, L858R, or T790M mutations
Major Interaction
Strong CYP3A4 inducers reduce efficacy by ~78%
Boxed Warning
QTc prolongation — ECG monitoring required
Research grant prospecting
Find open funding opportunities from NIH, NSF, Wellcome Trust, and other foundations relevant to your research area. Surface calls for proposals with sufficient lead time to prepare competitive applications.
Find current NIH R01 and R21 grant opportunities for mitochondrial dysfunction in metabolic disease research, with deadlines in the next 4 months.
Found 7 active opportunities. Top match: NIH R01 PA-25-090 (Mitochondrial Biology, $500K/yr, deadline May 5). Also: R21 exploratory grant for novel mitochondrial targets ($275K, Jun 16).
ToolRouter search_grants
MechanismFoaCeiling
R01PA-25-090 · Mitochondrial Biology$500K/yr
R21PA-25-118 · Novel Mitochondrial Targets$275K
7 active opportunities · R01 and R21 mechanisms
Competitive research landscape analysis
Understand the commercial and academic landscape around your research targets. Identify which companies are developing drugs against your proteins of interest and what stage their programs are at.
Research the competitive landscape for GLP-1 receptor agonist development: who are the major players, what differentiation strategies are emerging, and what targets are still underexplored?
Landscape covers 23 companies. Novo Nordisk and Eli Lilly dominate with semaglutide/tirzepatide. Emerging differentiation: oral formulations (4 programs), CNS-targeted variants (3), once-monthly dosing (6). Underexplored: GLP-1R partial agonism and dual CNS/peripheral targets.
ToolRouter research
Total Programs
23 companies in active development
Market Leaders
Novo Nordisk (semaglutide) · Eli Lilly (tirzepatide)
Oral Formulations
4 programs in development — key differentiator
Once-Monthly Dosing
6 programs targeting monthly injection
Underexplored
GLP-1R partial agonism · dual CNS/peripheral targets
Ready-to-use prompts
Compound safety lookup
Look up dimethyl sulfoxide (DMSO): molecular formula, boiling point, GHS hazard classification, and any known effects on cell membrane permeability at concentrations above 1%.
Literature search
Find peer-reviewed papers from 2022–2026 on liquid-liquid phase separation in RNA-binding proteins. Include citation counts and focus on those proposing therapeutic targets.
Clinical trial search
Find Phase 1 and Phase 2 trials for CAR-T cell therapies targeting solid tumors that are currently recruiting. Include NCT number, sponsor, tumor type, and enrollment size.
Drug mechanism lookup
Pull FDA labeling for venetoclax: mechanism of action, approved indications, dosing schedule, and the boxed warning details.
Grant opportunities
Find current NIH and European Research Council grants for epigenetic regulation of gene expression research. Show funding ceiling, mechanism type, and submission deadline.
Element data
Give me the full periodic table entry for selenium: atomic number, electron configuration, oxidation states, biological roles, and known toxicity thresholds.
Research landscape
Research the current state of antibody-drug conjugate (ADC) development: approved drugs, mechanisms of action, linker chemistry evolution, and next-generation approaches in clinical trials.
Nutrition biochemistry
Look up the nutritional profile and biochemical roles of coenzyme Q10: biosynthesis pathway, mitochondrial function, dietary sources, and evidence for supplementation in cardiovascular disease.
Tools to power your best work
Academic ResearchSearch papers, authors, citations
Competitor ResearchDeep intel from a single URL
Content RepurposerTurn any content into posts, scripts, and articles
Deep ResearchAI research reports with citations
Drug InformationDrug info: recalls & side effects
Chemistry LookupCompounds, elements, and safety
Clinical TrialsClinical trials & drug safety data
Grants FinderFind grants, funding fits, and precedent
165+ tools.
One conversation.
Everything biochemists need from AI, connected to the assistant you already use. No extra apps, no switching tabs.
Drug target validation pipeline
Validate a biochemical target from first principles: literature support, known chemical matter, clinical precedent, and competitive landscape.
Grant proposal preparation
Find the right funding opportunity, gather literature support, and compile the background data needed for a competitive research proposal.
Lab safety and reagent preparation
Before ordering or using new reagents, look up all relevant safety, handling, and biological activity data.
Frequently Asked Questions
How comprehensive is the chemistry compound database?
Chemistry Lookup draws from PubChem and other public chemical databases covering millions of compounds. It provides molecular formulas, SMILES notation, GHS hazard data, and known biological activities for most commercially available research chemicals.
Can I search for papers from specific journals or authors?
Academic Research supports filtering by author name, institution, and publication year. Journal filtering is available for many indexed publications. It searches across PubMed, CrossRef, Semantic Scholar, and arXiv preprints.
How up to date is the clinical trials data?
Clinical Trials data is sourced from ClinicalTrials.gov, which is updated by sponsors on an ongoing basis. Status changes typically reflect within days of the official update.
Can I use these tools to write grant applications?
These tools help you research, gather supporting data, and identify funding opportunities — which are the most time-intensive parts of grant writing. The actual writing requires your scientific expertise, but the background compilation is dramatically accelerated.
Does drug information include veterinary or investigational drugs?
Drug Information primarily covers FDA-approved human drugs. Investigational NDA compounds and some off-label data are included where public FDA records exist. Veterinary drug coverage is limited.
Give your AI superpowers.
Get started for free
Works in Chat, Cowork and Code